Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


Publication year:
All
1 - 7 out of 7Page size: 10
  1. 2010
  2. Published

    Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling

    Hasselbalch, B., Lassen, Ulrik Niels, Poulsen, H. S. & Stockhausen, M., 1 Oct 2010, In: Cancer Investigation. 28, 8, p. 775-87 13 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan

    Hasselbalch, B., Eriksen, J. G., Broholm, H., Christensen, I. J., Grunnet, K., Horsman, M. R., Poulsen, H. S., Stockhausen, M. & Lassen, Ulrik Niels, 1 Aug 2010, In: Acta Pathologica Microbiologica et Immunologica Scandinavica. 118, 8, p. 585-94 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan

    Hasselbalch, B., Eriksen, J. G., Broholm, H., Christensen, I. J., Grunnet, K., Horsman, M. R., Poulsen, H. S., Stockhausen, M. & Lassen, Ulrik Niels, Aug 2010, In: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 118, 8, p. 585-94 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

    Lassen, Ulrik Niels, Molife, L. R., Sorensen, J. M., Engelholm, S., Vidal, L., Sinha, R., Penson, R. T., Buhl-Jensen, P., Crowley, E., Tjornelund, J., Knoblauch, P., de Bono, J. S. & Buhl-Jensen, P., 29 Jun 2010, In: B J C. 103, 1, p. 12-7 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

    Hasselbalch, B., Lassen, Ulrik Niels, Hansen, S., Holmberg, M., Sørensen, M., Kosteljanetz, M., Broholm, H., Stockhausen, M. & Poulsen, H. S., 1 May 2010, In: Neuro-Oncology. 12, 5, p. 508-16 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

    Hasselbalch, B., Lassen, Ulrik Niels, Hansen, S., Holmberg, M., Sørensen, M., Kosteljanetz, M., Broholm, H., Stockhausen, M. & Poulsen, H. S., May 2010, In: Neuro-Oncology. 12, 5, p. 508-16 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer

    Rohrberg, K. S., Skov, B. G., Lassen, Ulrik Niels, Christensen, I. J., Høyer-Hansen, G., Buysschaert, I. & Pappot, Helle, 1 Jan 2010, In: Cancer Biomarkers. 7, 3, p. 141-51 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

ID: 4952653